Dynatrace financials
$57.53−0.54%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Mar 31 | FY25 Mar 31 | FY24 Mar 31 | FY23 Mar 31 | FY22 Mar 31 | FY21 Mar 31 | FY20 Mar 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.02B | $1.70B | $1.43B | $1.16B | $929.4M | $703.5M | $545.8M |
| Gross profit | $1.65B | $1.38B | $1.16B | $935.6M | $756.6M | $575.8M | $416.9M |
| Gross margin | 81.6% | 81.2% | 81.4% | 80.8% | 81.4% | 81.8% | 76.4% |
| Operating income | $245.4M | $179.4M | $128.4M | $92.8M | $81.3M | $91.9M | -$171.9M |
| Net income | $162.7M | $483.7M | $154.6M | $108.0M | $52.5M | $75.7M | -$413.8M |
| Net margin | 8.1% | 28.5% | 10.8% | 9.3% | 5.6% | 10.8% | −75.8% |
| Diluted EPS | $0.54 | $1.59 | $0.52 | $0.37 | $0.18 | $0.26 | $-1.56 |
| EBITDA | $288.0M | $227.5M | $183.3M | $147.4M | $138.2M | $152.9M | -$104.5M |
| Operating cash flow | $561.9M | $459.4M | $378.1M | $354.9M | $250.9M | $220.4M | -$142.5M |
| Free cash flow | $529.7M | $433.3M | $351.6M | $333.3M | $233.2M | $206.6M | -$163.1M |
| Diluted shares | 303.7M | 303.6M | 299.3M | 291.6M | 290.9M | 286.5M | 264.9M |
Balance sheet
| Period end | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.10B | $1.02B | $779.0M | $555.3M | $463.0M | $325.0M |
| Short-term investments | $74.9M | $96.2M | $57.9M | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $273.9M | $391.9M |
| Total assets | $4.42B | $4.14B | $3.41B | $2.77B | $2.54B | $2.26B |
| Total liabilities | $1.80B | $1.52B | $1.39B | $1.16B | $1.24B | $1.14B |
| Shareholders' equity | $2.61B | $2.62B | $2.02B | $1.60B | $1.30B | $1.11B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology